Analysts Offer Insights on Healthcare Companies: Syros Pharmaceuticals (SYRS), Alpine Immune Sciences (ALPN) and TransCode Therapeutics (RNAZ)
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target
TransCode Therapeutics Analyst Ratings
Promising Preliminary Clinical and Preclinical Results Bolster Buy Rating for TransCode Therapeutics: An Analysis by Emily Bodnar
TransCode Therapeutics Analyst Ratings
H.C. Wainwright Initiates a Buy Rating on TransCode Therapeutics (RNAZ)
Analysts Offer Insights on Healthcare Companies: TransCode Therapeutics (RNAZ), Tarsus Pharmaceuticals (TARS) and Roivant Sciences (ROIV)
TransCode Therapeutics (RNAZ) Gets a Buy From H.C. Wainwright
H.C. Wainwright Sticks to Its Buy Rating for TransCode Therapeutics (RNAZ)
HC Wainwright Adjusts Price Target on TransCode Therapeutics to $6 From $10, Maintains Buy Rating
TransCode Therapeutics Analyst Ratings
H.C. Wainwright Remains a Buy on TransCode Therapeutics (RNAZ)
HC Wainwright Starts TransCode Therapeutics at Buy With $10 Price Target
Transcode Therapeutics Price Target Announced at $10.00/Share by HC Wainwright & Co.
Transcode Therapeutics Initiated at Buy by HC Wainwright & Co.
TransCode Therapeutics analyst ratings
HC Wainwright & Co. Initiates Coverage On TransCode Therapeutics with Buy Rating, Announces Price Target of $10
No Data